1P-LSD (1-propionyl-lysergic acid diethylamide) is a synthetic psychedelic of the lysergamide family that functions as a prodrug for LSD-25 -- meaning your body converts it into actual LSD before it does anything. This is not a theory or a reasonable inference; it was demonstrated directly in a 2020 human pharmacokinetic study by Brandt et al., which showed 1P-LSD serum levels plummeting within the first hour of ingestion while LSD levels rose in lockstep. By the time you are feeling anything, the molecule responsible is plain LSD. The propionyl group -- a small three-carbon chain bolted onto the nitrogen at position 1 of the lysergamide skeleton -- is just a ticket through the door. Plasma esterases strip it off, and what remains is the same molecule Albert Hofmann rode his bicycle on in 1943.
1P-LSD first appeared on the research chemical market around 2015 and rapidly became the most popular and thoroughly documented lysergamide analog in history. It was designed, frankly, as a legal hack: by attaching a propionyl group to LSD, chemists created a molecule that was not LSD under the letter of most drug scheduling laws while converting to LSD with near-complete efficiency inside the human body. The strategy worked for years. 1P-LSD became the gateway through which tens of thousands of people accessed the LSD experience in jurisdictions where LSD itself was tightly scheduled, and it generated one of the richest bodies of community trip reports, microdosing data, and comparative analysis in the research chemical world. The Reddit communities alone contain thousands of detailed first-person accounts spanning everything from first-time 100 µg experiences to extended microdosing protocols.
The practical difference between 1P-LSD and LSD is small but real: onset takes 45-90 minutes instead of LSD's typical 30-60 minutes, because the prodrug conversion adds a metabolic step before the active molecule reaches your brain. Once it arrives, the experience is pharmacologically identical -- same receptor binding, same duration (8-12 hours), same visual character, same emotional depth. Experienced users in blinded comparisons consistently cannot tell them apart. The slightly longer come-up is the only reliable distinguishing feature, and it is also the most common source of dosing accidents, because impatient first-timers redose during the quiet window and end up with twice what they intended.
1P-LSD's significance extends beyond recreation. It provided a legal channel through which researchers in restricted jurisdictions could study lysergamide pharmacology, and the massive community dataset it generated -- particularly around microdosing -- has informed clinical thinking about LSD's sub-perceptual effects. Its regulatory cat-and-mouse story also spawned an entire lineage of successor prodrugs: 1cP-LSD, 1V-LSD, 1B-LSD, and 1D-LSD, each engineered to stay one step ahead of evolving legislation while exploiting the same esterase-cleavage mechanism.
What the Community Wants You to Know
Long-term 1P-LSD microdosers consistently report improved mood, enhanced creativity, and greater social openness as the primary benefits. Cognitive enhancement and focus improvements are also frequently mentioned but tend to be more subtle and dose-dependent.
The Fadiman protocol (dose every 3rd day) is the most commonly used schedule for 1P-LSD microdosing. Some users with depression find the off-days difficult and experiment with every-other-day dosing, though tolerance buildup is a concern with more frequent schedules.
Taking 1P-LSD alongside SSRIs or SNRIs significantly dulls the effects due to serotonin receptor competition. Users on Effexor, Lexapro, and similar medications report needing to skip their medication or finding reduced efficacy. Never alter psychiatric medication without consulting a doctor.
Safety at a Glance
High Risk- P-LSD is microgram-for-microgram equivalent to LSD in potency, confirmed by both human pharmacokinetic data and exten...
- Microdose: 5-15 µg (sub-perceptual; Fadiman protocol: one dose every three days)
- Toxicity: Acute Toxicity Because 1P-LSD converts to LSD with near-complete efficiency, its toxicity profile is functionally ide...
- Overdose risk: Can You Overdose on 1P-LSD? A fatal pharmacological overdose on 1P-LSD is extraordinarily unlikel...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 8 hrs – 12 hrsHow It Feels
The first thirty minutes are quiet, and that quietness is important to understand. Unlike LSD blotter, where something usually stirs within twenty minutes, 1P-LSD takes its time. The propionyl group needs to be stripped away by your body's enzymes before the real molecule reaches your brain. You might feel a subtle restlessness -- a faint electric tingling in the limbs, a slight quickening of attention -- but the early period is often calm enough to make you wonder if it is working at all. This window is where most dosing mistakes happen: the wait feels long, the doubt creeps in, and the temptation to take more is real. Resist it. Everything that follows will confirm that the first dose was doing its job all along.
Around the forty-five to seventy-five minute mark, the shift becomes unmistakable. Colors begin to saturate as though someone is slowly turning up the contrast on reality. The green of a leaf becomes impossibly vivid, almost neon. Surfaces develop a gentle breathing quality -- walls expanding and contracting like something alive is behind them. Your thoughts begin branching: one idea triggers three, each of those triggers three more, and suddenly you are following conceptual threads that weave together in ways that feel simultaneously obvious and impossible. A restless energy fills the body, making it hard to sit still. There may be a wave of nausea or a fluttery tightness in the stomach -- the body acknowledging the transition, not fighting it.
The peak arrives somewhere between two and four hours and it is unmistakably LSD. Geometric patterns tessellate across every surface -- spirals, lattices, fractals emerging from wood grain, carpet texture, the veins of your own hands. Closed-eye visuals range from intricate mandala structures to vast architectural spaces made of light and mathematics. Music transforms completely: it stops being something you listen to and becomes something that happens to you, each note carrying weight, color, spatial dimension. Emotional sensitivity is staggering. A fleeting thought about someone you love can produce waves of tenderness so intense they bring tears. An offhand worry can unfold into a fractal of anxiety that requires active management. At doses above 150 µg, the boundary between self and world softens dramatically. The sense of being a separate observer can dissolve into something boundary-less -- what people call ego dissolution, and what the experience genuinely feels like is the universe briefly examining itself through you.
The descent stretches four to six hours and it is gentle. The wild geometric intensity fades into a lingering shimmer. Surfaces still breathe faintly. Thoughts lose their manic acceleration but retain an unusual lateral quality -- connections keep appearing between ideas that sober thinking would never link. Many people find this phase the most valuable: the intensity has receded enough for conversation and reflection, but the perceptual openness remains. There is a bone-deep physical tiredness and a characteristic emotional tenderness toward the world. Music still sounds extraordinary. Sleep remains elusive for another hour or two. The afterglow -- heightened color perception, quiet wonder, emotional openness -- can persist into the next day and sometimes longer.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(23)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Increased salivation— Increased salivation (hypersalivation or sialorrhea) is the excessive production of saliva beyond wh...
- Insomnia— A persistent inability to fall asleep or maintain sleep despite physical tiredness, often characteri...
- Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
- Muscle tension— Persistent partial contractions or tightening of muscles that produces uncomfortable stiffness, cram...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Physical fatigue— Physical fatigue is a state of bodily exhaustion characterized by reduced energy, diminished capacit...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(20)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- External hallucination— A visual hallucination that manifests within the external environment as though it were physically r...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Recursion— The visual field begins to repeat and nest within itself in a self-similar, fractal-like manner, as ...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Texture liquidation— Surfaces and textures progressively smooth and simplify until the environment takes on the fluid, st...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(31)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Catharsis— A powerful emotional release and cleansing involving the surfacing, processing, and resolution of de...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Ego replacement— Ego replacement is the experience of one's usual personality and sense of self being completely over...
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Multiple thought streams— The experience of having more than one internal narrative or stream of consciousness simultaneously ...
- Music appreciation enhancement— A profound enhancement of one's enjoyment and emotional connection to music, making songs feel deepl...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Panic attack— A panic attack is a discrete episode of acute, overwhelming fear or terror that arises suddenly and ...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Personal meaning enhancement— Personal meaning enhancement is a state in which everyday events, coincidences, song lyrics, environ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Suggestibility enhancement— Heightened receptivity to external suggestions, ideas, and influence, commonly experienced during ps...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought disorganization— Thought disorganization is a cognitive impairment in which the normal capacity for structured, seque...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(4)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Multi-sensory(3)
- Machinescapes— Machinescapes are complex multisensory hallucinations involving the perception of enormous mechanica...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(4)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Spirituality enhancement— A profound intensification of spiritual feelings, mystical awareness, and a sense of sacred connecti...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Community Insights
Community Wisdom(4)
Long-term 1P-LSD microdosers consistently report improved mood, enhanced creativity, and greater social openness as the primary benefits. Cognitive enhancement and focus improvements are also frequently mentioned but tend to be more subtle and dose-dependent.
Based on 4 community posts · 257 combined upvotes
1P-LSD is a prodrug that converts to LSD-25 in the body. The community consensus is that 100ug of 1P-LSD is roughly equivalent to 75ug of LSD-25 in subjective potency, so dosages should be adjusted accordingly.
Based on 4 community posts · 59 combined upvotes
The legal status of 1P-LSD varies significantly by jurisdiction. While it exists in a legal gray area in some countries as a research chemical, others have explicitly scheduled it under analogue acts. Always check your local laws before purchasing.
Based on 2 community posts · 46 combined upvotes
1P-LSD has a slightly slower onset than LSD-25, typically taking 30-60 minutes to begin effects compared to 20-40 minutes for street LSD. This is because 1P-LSD must first be metabolized into LSD-25 before becoming active.
Based on 3 community posts · 22 combined upvotes
Dosage Guidance(4)
The Fadiman protocol (dose every 3rd day) is the most commonly used schedule for 1P-LSD microdosing. Some users with depression find the off-days difficult and experiment with every-other-day dosing, though tolerance buildup is a concern with more frequent schedules.
Based on 3 community posts · 120 combined upvotes
A dose of 25ug of 1P-LSD sits in the threshold range between microdose and trip dose. Users report noticeably enhanced energy, motivation, and mild perceptual shifts at this level without full psychedelic effects. This is sometimes called a minidose.
Based on 2 community posts · 54 combined upvotes
For microdosing 1P-LSD, most users find their sweet spot between 7-15ug. Starting at 5ug and titrating upward by 1-2ug increments over successive doses is the safest approach to finding your personal threshold.
Based on 4 community posts · 29 combined upvotes
Volumetric dosing with 1P-LSD is the preferred method for accurate microdoses. Dissolve a 100ug tab in 100ml of vodka or distilled water in an amber glass bottle, then measure doses with a 1ml syringe. Store in the fridge or freezer to maintain potency.
Based on 3 community posts · 27 combined upvotes
Harm Reduction(4)
Taking 1P-LSD alongside SSRIs or SNRIs significantly dulls the effects due to serotonin receptor competition. Users on Effexor, Lexapro, and similar medications report needing to skip their medication or finding reduced efficacy. Never alter psychiatric medication without consulting a doctor.
Based on 2 community posts · 93 combined upvotes
1P-LSD still reacts with Ehrlich reagent, turning purple after a slightly longer reaction time than LSD-25. Testing your tabs is still important even with research chemicals from reputable vendors, as mislabeled or degraded product is always possible.
Based on 2 community posts · 49 combined upvotes
After a full-dose trip, wait at least two weeks before microdosing again to allow tolerance to fully reset. For microdosing, a minimum of 2 days between doses helps prevent rapid tolerance buildup that would require escalating doses.
Based on 2 community posts · 39 combined upvotes
Sleep disruption is a common side effect of 1P-LSD microdosing, especially in the first few sessions. Dosing early in the morning (before 10am) and avoiding afternoon doses helps minimize insomnia. Some users find CBD oil in the evening counteracts residual stimulation.
Based on 3 community posts · 24 combined upvotes
Common Misconceptions(1)
Many users report 1P-LSD feels slightly cleaner or milder than street LSD, but this is likely due to precise dosing on lab-produced tabs rather than any inherent pharmacological difference. Once metabolized, 1P-LSD and LSD-25 produce the same active compound.
Based on 4 community posts · 59 combined upvotes
Combination Warnings(1)
Mixing 1P-LSD microdoses with cannabis can unpredictably intensify effects and increase anxiety. Users who previously relied on cannabis report that 1P-LSD microdosing helped reduce their desire to smoke, but combining the two substances is generally discouraged.
Based on 2 community posts · 26 combined upvotes
Set & Setting(1)
Microdosing 1P-LSD on workdays requires careful dose calibration. Multiple users report that 13-15ug can be too stimulating for focused office work, causing restlessness and difficulty concentrating. Keeping work-day doses at 7-10ug is generally recommended.
Based on 3 community posts · 22 combined upvotes
Pharmacology
Mechanism of Action
1P-LSD is a prodrug. It has essentially no direct psychoactive activity of its own. When you ingest 1P-LSD, esterases in plasma and intestinal tissue cleave the propionyl ester bond at the N1 position, releasing LSD-25 into systemic circulation. The 2020 Brandt et al. human pharmacokinetic study provided definitive proof: after oral administration, 1P-LSD serum concentrations dropped sharply within 60 minutes while LSD concentrations rose proportionally. Only LSD was detected in urine. Bioavailability of LSD from oral 1P-LSD approaches 100%, making it one of the most efficient prodrug conversions in pharmacology.
Once released, LSD acts as a biased partial agonist at serotonin 5-HT2A receptors -- the principal molecular target for classical psychedelic effects. These receptors are concentrated in layer V pyramidal neurons of the prefrontal cortex. LSD binds deep within the receptor's ligand pocket, and a flexible extracellular loop then folds over the molecule like a lid, trapping it inside. This "lid" mechanism explains why LSD's subjective effects persist for 8-12 hours despite a plasma half-life of only 3.6 hours: the drug is physically locked into the receptor long after blood levels have declined.
Receptor Targets (via LSD)
- 5-HT2A receptors -- Primary psychedelic target. Biased partial agonism with preferential beta-arrestin pathway activation disrupts the brain's predictive coding hierarchy, flooding conscious awareness with sensory information normally filtered out
- 5-HT1A receptors -- Partial agonist. Provides the anxiolytic, contemplative undercurrent that distinguishes LSD from harsher 5-HT2A agonists
- 5-HT2C receptors -- Agonist. Contributes to mood modulation and the anxiogenic edge at higher doses
- Dopamine D2/D3 receptors -- Moderate affinity. This is why LSD (and therefore 1P-LSD) feels more stimulating and electrically charged than psilocybin or other tryptamine psychedelics. The dopaminergic component drives the mental acceleration, enhanced sociability, and that characteristic "speedy" quality
- Alpha-adrenergic receptors -- Mydriasis, mild tachycardia, peripheral vasoconstriction
- Histamine H1 receptors -- Mild sedative component at lower doses
Pharmacokinetics
Onset: 45-90 minutes (15-30 minutes longer than LSD due to the prodrug conversion step). Peak effects: 2-4 hours post-ingestion. Total duration: 8-12 hours, identical to LSD. The prodrug conversion is rapid and nearly complete -- 1P-LSD serum levels are negligible by 60-90 minutes, meaning the active phase is driven entirely by LSD kinetics. The plasma half-life of LSD (approximately 3.6 hours) understates the duration of action because of the receptor-locking mechanism described above.
Tolerance
Tolerance develops rapidly -- within 24-48 hours of a single dose. Complete cross-tolerance exists with all serotonergic psychedelics (LSD, psilocybin, mescaline, DMT analogs). Baseline sensitivity returns in approximately 5-7 days, which naturally prevents compulsive daily use. Microdosing protocols (Fadiman: one dose every three days; Stamets: four days on, three off) are designed to operate within this tolerance window.
Detection Methods
Urine Detection
1P-LSD and its metabolites are not targeted by standard immunoassay-based urine drug screens. Because lysergamides are active at microgram doses, the absolute quantity of drug and metabolite present in biological samples is extremely low, making detection inherently difficult. Specialized urine assays using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify lysergamide metabolites within approximately 24 to 72 hours after ingestion, though this window is shorter than most other drug classes due to rapid metabolism and renal clearance.
Blood and Serum Detection
Blood detection windows for 1P-LSD are narrow. Plasma concentrations peak within 1 to 3 hours of oral administration and fall below detectable thresholds within 6 to 12 hours for most analytical methods. LC-MS/MS can extend this window modestly, but serum testing for lysergamides is rarely performed outside of forensic or research contexts due to the specialized equipment required and the very low concentrations involved.
Standard Drug Panel Inclusion
1P-LSD is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. These panels test for amphetamines, cannabinoids, cocaine metabolites, opiates, and PCP (with extended panels adding benzodiazepines, barbiturates, and similar classes). Lysergamides do not cross-react with any of these immunoassay targets. Detection requires a specific request for lysergamide testing, which is uncommon in workplace, probationary, or emergency department screening.
Confirmatory Methods
When lysergamide use is specifically suspected, confirmatory testing relies on LC-MS/MS or gas chromatography-mass spectrometry (GC-MS). LC-MS/MS is the preferred method due to its superior sensitivity at picogram-per-milliliter concentrations. Immunoassay-based LSD-specific screens exist but suffer from high false-negative rates with novel lysergamide analogs, as antibody cross-reactivity varies between compounds.
Reagent Testing (Harm Reduction)
For harm reduction identification, the Ehrlich reagent is the primary tool for 1P-LSD. A small sample placed on the reagent should produce a purple to violet color change, indicating the presence of an indole moiety characteristic of lysergamides. The Hofmann reagent provides a confirmatory blue to purple reaction. Importantly, the Marquis reagent shows no reaction or a faint olive discoloration with lysergamides, which helps distinguish them from other compound classes. A positive Ehrlich result does not confirm the specific lysergamide identity but does rule out NBOMe and NBOH compounds, which show no Ehrlich reaction. Using both Ehrlich and Hofmann reagents together provides greater confidence in lysergamide identification.
Interactions
Popular Combinations
“Mixing 1P-LSD microdoses with cannabis can unpredictably intensify effects and increase anxiety. Users who previously relied on cannabis report that 1P-LSD microdosing helped reduce their desire to smoke, but combining the two substances is generally discouraged.”
26| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Origin of the Prodrug Strategy
The idea of N1-acylated LSD analogs is not new. ALD-52 (1-acetyl-LSD) was synthesized by Albert Hofmann himself at Sandoz Laboratories decades before 1P-LSD existed. The acetyl group at N1 was known to be hydrolyzed in biological systems, effectively converting ALD-52 into LSD. ALD-52 became briefly notorious in 1969 when it was implicated in "Orange Sunshine" -- a famous batch of acid distributed by the Brotherhood of Eternal Love, though this attribution remains disputed. The pharmacological principle was established: attach a small acyl group to the N1 nitrogen, and the body will remove it, releasing LSD.
Emergence on the Research Chemical Market (2015)
1P-LSD first appeared on the European research chemical market in approximately January 2015, sold as blotters and powdered material through online vendors operating primarily from Germany and the Netherlands. No prior published chemical, analytical, or pharmacological data existed for the compound. It was introduced explicitly as a legal alternative to LSD, designed to exploit the structural specificity of drug scheduling laws -- the propionyl modification created a molecule not explicitly listed in most controlled substance schedules while converting to the scheduled compound inside the body.
Scientific Characterization (2016-2020)
The first peer-reviewed analysis came from Brandt et al. in 2016, published as "Return of the lysergamides. Part I" in Drug Testing and Analysis. This study provided analytical profiles and demonstrated that 1P-LSD produced LSD-like head-twitch responses in C57BL/6J mice at approximately 38% of LSD's potency -- consistent with a prodrug mechanism where conversion is only partial before the behavioral measurement window closes. The definitive human evidence came in 2020: Brandt et al. published pharmacokinetic data from two male volunteers showing that only LSD appeared in serum and urine after 1P-LSD administration, with bioavailability approaching 100%.
Regulatory Response and the Successor Chain
Germany's Neue-psychoaktive-Stoffe-Gesetz (NpSG), enacted in November 2016, was among the first laws to capture 1P-LSD through generic structural definitions rather than substance-specific scheduling. This legislative action triggered a pattern that would repeat across the next decade: each time a jurisdiction scheduled a specific prodrug, the research chemical market responded with a new N1-acyl variant. 1cP-LSD (1-cyclopropanoyl-LSD) appeared around 2019 to circumvent the German NpSG. 1V-LSD (1-valeroyl-LSD, also called "Valerie") followed in 2021. 1B-LSD (1-butanoyl-LSD) and 1D-LSD emerged subsequently. Each exploited the same enzymatic mechanism -- esterase cleavage of the N1 acyl group -- and each generated its own wave of community reports confirming experiential equivalence with LSD.
Legacy
1P-LSD is no longer the dominant legal lysergamide in most markets, having been superseded by whatever analog currently evades local scheduling. But its significance is lasting: it was the proof-of-concept that established the N1-acyl prodrug strategy as commercially viable, generated the largest community dataset of any research chemical psychedelic, and provided a legal framework through which informal human research on LSD pharmacology continued during years when formal clinical access remained extremely restricted.
Harm Reduction
Test It
Ehrlich reagent is non-negotiable. A drop on a tiny corner of the tab should produce a purple or violet reaction within minutes, confirming the presence of an indole compound. This tells you it is a lysergamide and not an NBOMe, DOx, or other dangerous blotter-active chemical. NBOMe compounds have killed people at doses safe for actual lysergamides. A Hofmann reagent (blue reaction) provides secondary confirmation. If the tab produces no Ehrlich reaction, do not take it.
Dosing
1P-LSD is microgram-for-microgram equivalent to LSD in potency, confirmed by both human pharmacokinetic data and extensive community reports:
- Microdose: 5-15 µg (sub-perceptual; Fadiman protocol: one dose every three days)
- Threshold: 15-25 µg
- Light: 25-75 µg
- Common: 75-150 µg
- Strong: 150-300 µg
- Heavy: 300+ µg
First-timers: 75-100 µg provides a meaningful, manageable experience. Start there, not higher.
The Come-Up Trap
This is the single most important practical harm reduction point for 1P-LSD specifically. Onset takes 45-90 minutes -- noticeably longer than LSD blotter. During this window, you may feel nothing or almost nothing. The temptation to redose is strong. Do not. Many of the worst experiences reported with 1P-LSD trace back to someone taking a second dose at the 60-minute mark and then peaking on double their intended amount. Wait a full two hours before concluding the dose was insufficient.
Set and Setting
Everything that applies to LSD applies identically here:
- Mindset: Only dose in a stable emotional state. Anxious, grieving, or in crisis? Postpone. 1P-LSD amplifies whatever you bring to it
- Environment: Familiar, comfortable, safe. Nature is consistently rated the best setting. Avoid crowds, strangers, and obligations
- Trip sitter: A sober, trusted person for first experiences or doses above 100 µg. This single precaution prevents more bad outcomes than any other measure
Dangerous Combinations
- Lithium -- Absolute contraindication. Documented seizures and cardiac events with lysergamides. This combination can kill
- MAOIs -- Serotonin syndrome risk. Do not combine
- Tramadol -- Lowers seizure threshold significantly
- Cannabis -- The most commonly reported escalator of difficult experiences. Dramatically and unpredictably amplifies intensity and paranoia. The community consensus is unambiguous: avoid cannabis during the peak
- Stimulants -- Cardiovascular strain and psychological overstimulation
If Things Get Difficult
- Change the environment: different room, go outside, change the music
- Grounding techniques: cold water on face and wrists, slow breathing, physical contact with a trusted person
- Simple reassurance: "You took a substance. This will pass. You are safe"
- Benzodiazepines (diazepam 10-20 mg) reliably reduce intensity and are widely kept on hand by experienced users as an emergency brake
- Do not use antipsychotics as a first option
Toxicity & Safety
Acute Toxicity
Because 1P-LSD converts to LSD with near-complete efficiency, its toxicity profile is functionally identical to LSD-25 -- one of the most thoroughly studied psychoactive substances in existence. LSD has an estimated LD50 of 16-46 mg/kg in mice (intravenous), which extrapolates to a human lethal dose thousands of times above any recreational amount. No pharmacological fatality from LSD or any confirmed LSD prodrug has ever been documented in the medical literature.
Cardiovascular Effects
Mild sympathomimetic effects at standard doses: heart rate elevation of approximately 10-20 bpm, modest blood pressure increase, pupil dilation (mydriasis), peripheral vasoconstriction. These effects are well-tolerated in healthy individuals. Contraindicated in individuals with significant cardiovascular disease, arrhythmias, or uncontrolled hypertension.
Psychological Risks
The real dangers of 1P-LSD are psychological, not physical:
- Acute panic and anxiety -- The most common adverse event. Dose-dependent, amplified by unfamiliar settings or cannabis co-use. Community reports describe these experiences as indistinguishable from LSD-induced panic
- Psychosis precipitation -- Absolute contraindication in individuals with personal or family history of schizophrenia, schizoaffective disorder, or bipolar I disorder. The prodrug mechanism does not diminish this risk in any way -- the active molecule is LSD
- HPPD (Hallucinogen Persisting Perception Disorder) -- Persistent visual disturbances (trailing images, halos, visual snow, geometric patterns in peripheral vision) have been reported following 1P-LSD use. Prevalence is unknown but appears to be low. Can persist for months to years in rare cases
- Integration difficulties -- High-dose ego-dissolution experiences can be destabilizing and may require professional support to process productively
Contraindications
- Personal or family history of schizophrenia, schizoaffective disorder, or bipolar I disorder
- Current lithium use (seizure and cardiac risk)
- Current MAOI use (serotonin syndrome risk)
- Tramadol use (lowered seizure threshold)
- Significant cardiovascular disease or uncontrolled hypertension
- Pregnancy or breastfeeding
Long-Term Toxicity
No formal long-term toxicity studies exist for 1P-LSD specifically. By analogy with LSD -- which shows no evidence of organ toxicity, carcinogenicity, or neurotoxicity at recreational doses across decades of research -- significant chronic physical toxicity is not expected. The rapid tolerance mechanism (5-7 day reset) naturally limits use frequency.
Addiction Potential
1P-LSD is not addictive. Because it converts to LSD in the body, its addiction profile is identical to LSD's, which is among the lowest of any psychoactive substance studied. LSD produces no physical dependence, no withdrawal syndrome, and no compulsive drug-seeking behavior in animal models -- laboratory animals consistently refuse to self-administer it, which is one of the strongest indicators of low abuse liability in preclinical pharmacology. Rapid tolerance development within 24-48 hours makes daily use functionally pointless: a second dose taken the day after the first will produce dramatically reduced effects, and a third even less. This tolerance resets over approximately one week, creating a natural pharmacological barrier to compulsive use patterns. Complete cross-tolerance with all serotonergic psychedelics (psilocybin, mescaline, DMT) further prevents substitution cycling. The community microdosing literature, which is extensive for 1P-LSD specifically, describes a common pattern of self-limiting use: people engage in structured protocols for weeks to months and then stop voluntarily, often reporting that the benefits persist after discontinuation. A small minority of users may develop patterns of psychological over-reliance on psychedelic experiences, but this is distinct from the compulsive escalating use that characterizes substance use disorders and is uncommon with lysergamides.
Overdose Information
Can You Overdose on 1P-LSD?
A fatal pharmacological overdose on 1P-LSD is extraordinarily unlikely. Because it converts to LSD, the lethal dose would be equivalent to LSD's estimated lethal threshold -- roughly 14,000 µg or more, which is 100-140 times a standard dose. No death from the pharmacological action of LSD or any confirmed LSD prodrug has ever been documented.
However, "overdose" in practical terms means taking more than you can psychologically manage. With 1P-LSD specifically, the extended come-up window (45-90 minutes) is the most common pathway to accidental high-dose experiences: users redose during the quiet period and end up at double their intended amount.
Recognizing a Crisis
Most situations involve psychological distress, not medical emergency. Seek immediate medical attention if someone exhibits:
- Hyperthermia -- Dangerously elevated body temperature is the most serious physical risk at extreme doses
- Seizures -- Rare with genuine lysergamides but possible with adulterants (NBOMe compounds especially)
- Signs of serotonin syndrome (if combined with serotonergic drugs): muscle rigidity, rapid temperature rise, confusion, clonus
- Complete unresponsiveness or catatonia
- Self-harm behavior or expressed suicidal intent
Psychological Distress Response
For someone having a difficult experience but not in medical danger:
- Change the environment immediately -- different room, go outside, change or stop the music
- Provide calm, grounding reassurance: "You are safe. You took a substance. This is temporary and it will end"
- Maintain physical presence. Do not leave a distressed person alone
- Cold water on face and wrists for grounding
- Benzodiazepines (diazepam 10-20 mg) reliably reduce intensity without dangerous interaction. Many experienced users keep these available as standard preparation
Medical Emergency Response
Call emergency services without hesitation for any physical safety concern. Good Samaritan laws in most jurisdictions protect people who call for help during drug emergencies. Inform responders that a lysergamide psychedelic was taken. There is no specific antidote; treatment is supportive (IV fluids, cooling for hyperthermia, benzodiazepines for agitation and seizures).
After a Difficult Experience
Talk through what happened with a trusted person within the first few days. Avoid additional psychedelic use for an extended period. Monitor for persistent symptoms -- anxiety, depersonalization, visual disturbances -- and seek professional help if they continue beyond two to three weeks.
Tolerance
| Full | almost immediately after ingestion |
| Half | 5-7 days |
| Zero | 14 days |
Cross-tolerances
Legal Status
Regulatory Overview
1P-LSD (1-propionyl-lysergic acid diethylamide) occupies a complex and evolving legal landscape. Because it is not explicitly listed in the United Nations Convention on Psychotropic Substances (1971), its control depends on how individual nations interpret analogue provisions or enact novel psychoactive substance (NPS) legislation.
United States
1P-LSD is not specifically scheduled under the Controlled Substances Act. However, theFederal Analogue Act (21 U.S.C. section 813) treats substances "substantially similar" in structure or effect to a Schedule I drug as Schedule I when intended for human consumption. Because 1P-LSD functions as a prodrug of LSD --- converting to LSD via hydrolysis in vivo --- prosecutors can invoke the Analogue Act when intent for human consumption is established. No federal court precedent has definitively adjudicated 1P-LSD under this provision as of early 2026.
Germany (NpSG)
Germany explicitly controls 1P-LSD under the Neue-psychoaktive-Stoffe-Gesetz (NpSG), enacted in November 2016 and subsequently amended. The NpSG uses a structural-class approach, scheduling entire chemical families rather than individual compounds. 1P-LSD was captured under amendments targeting lysergamide derivatives. Germany has progressively scheduled successor analogues including1cP-LSD (2019),1V-LSD (September 2022), and1D-LSD (2024) as each emerged on the market .
United Kingdom
The Psychoactive Substances Act 2016 provides a blanket ban on the production, supply, and possession with intent to supply of any substance capable of producing a psychoactive effect, with limited exceptions for alcohol, tobacco, caffeine, and regulated medicines. 1P-LSD falls squarely within this prohibition. Additionally, it was specifically listed as aClass A substance under theMisuse of Drugs Act 1971 via a 2015 amendment that captured several LSD-related compounds .
Other Jurisdictions
- Canada: Not specifically scheduled; the Controlled Drugs and Substances Act lists LSD but does not explicitly include 1P-LSD. However, enforcement agencies may pursue analogues under broader provisions.
- Japan: Controlled as adesignated substance (Shitei Yakubutsu) under the Pharmaceutical and Medical Device Act since April 2016 .
- Australia: Captured under Schedule 9 of the Poisons Standard as an analogue of LSD.
- Sweden & Denmark: Explicitly scheduled under national NPS legislation.
- Switzerland: Specifically banned.
References
Brandt SD, et al. Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). Drug Test Anal. 2016;8(9):891-902. Bundesministerium der Justiz. Neue-psychoaktive-Stoffe-Gesetz (NpSG). Available at: gesetze-im-internet.de. UK Home Office. The Misuse of Drugs Act 1971 (Amendment) Order 2015. Statutory Instrument 2015 No. 1503. Ministry of Health, Labour and Welfare (Japan). Designated Substances listing, 2016.
Experience Reports (6)
Tips (10)
For microdosing 1P-LSD, use volumetric dosing by dissolving a 100ug tab in 100ml of vodka or distilled water. This allows precise dosing with a syringe. Most people find their sweet spot between 5-15ug taken every 3 days.
1P-LSD is a prodrug of LSD with close to 100% bioavailability. A 2020 study on human volunteers confirmed that 1P-LSD rapidly converts to LSD in the body, making the subjective effects virtually indistinguishable.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid 1P-LSD and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
The Fadiman protocol (dose every 3 days) works well with 1P-LSD. Day 1 is dose day, Day 2 is the afterglow day where many report the best meditation sessions, and Day 3 is a baseline rest day.
If 10ug feels too strong for work (difficulty concentrating, dilated pupils), drop to 5-7ug. Many people report that 13ug and above starts to feel more like a threshold trip than a microdose, especially with no tolerance.
If you are on SSRIs, microdosing 1P-LSD may still produce subtle effects, but the interaction is not well studied. Some users report positive results combining the two, but always consult a medical professional and start with lower doses.
Community Discussions (12)
See Also
Same Class
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 1P-LSD - TripSit Factsheet
TripSit factsheet for 1P-LSD
tripsit - 1P-LSD - Wikipedia
Wikipedia article on 1P-LSD
wikipedia
Gallery